|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | XS0601 REDUCES THE INCIDENCE OF RESTENOSIS: A PROSPECTIVE STUDY OF 335 PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN CHINA显示文摘Background XS0601, consisting of active ingredients (Chuangxiongol and paeoniflorin), has been shown to inhibit arterial neointimal hyperplasia in animal models and in preliminary human studies. The objective of this study was to evaluate the safety and efficacy of XS0601 in preventing restenosis following percutaneous coronary intervention (PCI). Methods A multi-center, randomized, double-blind, placebo-controlled trial was conducted. A total of 335 patients were randomized into treatment with the oral administration of XS0601, or a placebo for 6 months after successful PCI. Angiographic follow-up was scheduled at 6 months, and clinical follow-ups performed at 1, 3 and 6 months after PCI. The primary end point was angiographic restenosis. The secondary end points were the combined incidence of death, target lesion nonfatal myocardial infarction, repeat angioplasty, and coronary artery bypass graft surgery. Results A total of 308 patients (91.9%) completed the study and 145 cases (47.1%) received angiographic follow-up. The restenosis rates were significantly reduced in the XS0601 group as compared with the placebo group (26.0% vs. 47.2%, P < 0.05), and the minimum lumen diameter (MLD) was greater [(2.08 ± 0.89) mm for XS0601 vs. (1.73 ± 0.94) mm for placebo, P < 0.05]. XS0601 also significantly reduced the combined incidence of major adverse cardiac event (10.4% in the XS0601 group vs. 22.7% in the placebo group, P < 0.05). The incidence of recurrent angina at 3 and 6 months after PCI was also significantly reduced in XS0601 group (7.1% and 11.0%) as compared with those in placebo group (19.5% and 42.9%) (P < 0.05). No significant side effects occurred within the 6-month follow-up period in the XS0601 group. Conclusion Administration of XS0601 for 6 months is demonstrated to be safe and effective in reducing restenosis in post-PCI patients. | CHEN Ke-ji SHI Da-zhuo XU Hao LUE Shu-zheng LI Tian-chang KE Yuan-nan ZHANG Min-zhou LU Xiao-yan SUN Rui-yuan YOU Shi-jie | 2006 | Chinese Medical Journal2006，，1： | 83 |
| 2 | Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission显示文摘Dear Editor,The occurrence of concentrated pneumonia cases in Wuhan city,Hubei province of China was first reported on December 30,2019 by the Wuhan Municipal Health Commission(WHO,2020).The pneumonia cases were found to be linked to a large seafood and animal market in Wuhan,and measures for sanitation and disinfection were taken swiftly by the local government agency.The Centers for Disease Control and Prevention(CDC)and Chinese health authorities later determined and announced that a novel coronavirus(CoV),denoted as 2019-nCoV,had caused the pneumonia outbreak in Wuhan city(CDC,2020).Scientists from multiple groups had obtained the virus samples from hospitalized patients(Normile,2020).The isolated viruses were morphologically identical when observed under electron microscopy. | Xintian Xu Ping Chen Jingfang Wang Jiannan Feng Hui Zhou Xuan Li Wu Zhong Pei Hao | 2020 | Science China(Life Sciences)2020，63，3： | 737 |
| 3 | A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus(2019-nCoV) infected pneumonia(standard version)显示文摘In December 2019, a new type viral pneumonia cases occurred in Wuhan, Hubei Province;and then named '2019 novel coronavirus(2019-nCoV)' by the World Health Organization(WHO) on 12 January 2020. For it is a never been experienced respiratory disease before and with infection ability widely and quickly, it attracted the world’s attention but without treatment and control manual. For the request from frontline clinicians and public health professionals of 2019-nCoV infected pneumonia management, an evidence-based guideline urgently needs to be developed. Therefore, we drafted this guideline according to the rapid advice guidelines methodology and general rules of WHO guideline development;we also added the first-hand management data of Zhongnan Hospital of Wuhan University. This guideline includes the guideline methodology, epidemiological characteristics, disease screening and population prevention, diagnosis, treatment and control(including traditional Chinese Medicine), nosocomial infection prevention and control, and disease nursing of the 2019-nCoV. Moreover, we also provide a whole process of a successful treatment case of the severe 2019-nCoV infected pneumonia and experience and lessons of hospital rescue for 2019-nCoV infections. This rapid advice guideline is suitable for the first frontline doctors and nurses, managers of hospitals and healthcare sections, community residents, public health persons, relevant researchers, and all person who are interested in the 2019-nCoV. | Ying-Hui Jin Lin Cai Zhen-Shun Cheng Hong Cheng Tong Deng Yi-Pin Fan Cheng Fang Di Huang Lu-Qi Huang Qiao Huang Yong Han Bo Hu Fen Hu Bing-Hui Li Yi-Rong Li Ke Liang Li-Kai Lin Li-Sha Luo Jing Ma Lin-Lu Ma Zhi-Yong Peng Yun-Bao Pan Zhen-Yu Pan Xue-Qun Ren Hui-Min Sun Ying Wang Yun-Yun Wang Hong Weng Chao-Jie Wei Dong-Fang Wu Jian Xia Yong Xiong Hai-Bo Xu Xiao-Mei Yao Yu-Feng Yuan Tai-Sheng Ye Xiao-Chun Zhang Ying-Wen Zhang Yin-Gao Zhang Hua-Min Zhang Yan Zhao Ming-Juan Zhao Hao Zi Xian-Tao Zeng Yong-Yan Wang Xing-Huan Wang 无 | 2020 | Military Medical Research2020，7，1： | 161 |
| 4 | Prevalence of Autism Spectrum Disorder in China:A Nationwide Multi-center Population-based Study Among Children Aged 6 to 12 Years显示文摘This study aimed to obtain the first national estimate of the prevalence of autism spectrum disorder(ASD) in Chinese children.We targeted the population of 6 to 12-year-old children for this prevalence study by multistage convenient cluster sampling.The Modified Chinese Autism Spectrum Rating Scale was used for the screening process.Of the target population of 142,086 children,88.5%(n=125,806) participated in the study.A total of 363 children were confirmed as having ASD.The observed ASD prevalence rate was 0.29%(95% CI:0.26%-0.32%) for the overall population.After adjustment for response rates,the estimated number of ASD cases was867 in the target population sample,thereby achieving an estimated prevalence of 0.70%(95% CI:0.64%-0.74%).The prevalence was significantly higher in boys than in girls(0.95%;95% CI:0.87%-1.02% versus 0.30%;95%CI:0.26%-0.34%;P <0.001).Of the 363 confirmed ASD cases,43.3% were newly diagnosed,and most of those(90.4%) were attending regular schools,and 68.8% of the children with ASD had at least one neuropsychiatric comorbidity.Our findings provide reliable data on the estimated ASD prevalence and comorbidities in Chinese children. | Hao Zhou Xiu Xu Weili Yan Xiaobing Zou Lijie Wu Xuerong Luo Tingyu Li Yi Huang Hongyan Guan Xiang Chen Meng Mao Kun Xia Lan Zhang Erzhen Li Xiaoling Ge Lili Zhang Chunpei Li Xudong Zhang Yuanfeng Zhou Ding Ding Andy Shih Eric Fombonne Yi Zheng Jisheng Han Zhongsheng Sun Yong-hui Jiang Yi Wang LATENT-NHC Study Team | 2020 | Neuroscience Bulletin2020，36，9： | 158 |
| 5 | Towards 6G wireless communication networks:vision,enabling technologies,and new paradigm shifts显示文摘The fifth generation(5G)wireless communication networks are being deployed worldwide from 2020 and more capabilities are in the process of being standardized,such as mass connectivity,ultra-reliability,and guaranteed low latency.However,5G will not meet all requirements of the future in 2030 and beyond,and sixth generation(6G)wireless communication networks are expected to provide global coverage,enhanced spectral/energy/cost efficiency,better intelligence level and security,etc.To meet these requirements,6G networks will rely on new enabling technologies,i.e.,air interface and transmission technologies and novel network architecture,such as waveform design,multiple access,channel coding schemes,multi-antenna technologies,network slicing,cell-free architecture,and cloud/fog/edge computing.Our vision on 6G is that it will have four new paradigm shifts.First,to satisfy the requirement of global coverage,6G will not be limited to terrestrial communication networks,which will need to be complemented with non-terrestrial networks such as satellite and unmanned aerial vehicle(UAV)communication networks,thus achieving a space-airground-sea integrated communication network.Second,all spectra will be fully explored to further increase data rates and connection density,including the sub-6GHz,millimeter wave(mmWave),terahertz(THz),and optical frequency bands.Third,facing the big datasets generated by the use of extremely heterogeneous networks,diverse communication scenarios,large numbers of antennas,wide bandwidths,and new service requirements,6G networks will enable a new range of smart applications with the aid of artificial intelligence(AI)and big data technologies.Fourth,network security will have to be strengthened when developing 6G networks.This article provides a comprehensive survey of recent advances and future trends in these four aspects.Clearly,6G with additional technical requirements beyond those of 5G will enable faster and further communications to the extent that the boundary between physical and cyber worlds disappears. | Xiaohu YOU Cheng-Xiang WANG Jie HUANG Xiqi GAO Zaichen ZHANG Mao WANG Yongming HUANG Chuan ZHANG Yanxiang JIANG Jiaheng WANG Min ZHU Bin SHENG Dongming WANG Zhiwen PAN Pengcheng ZHU Yang YANG Zening LIU Ping ZHANG Xiaofeng TAO Shaoqian LI Zhi CHEN Xinying MA Chih-Lin I Shuangfeng HAN Ke LI Chengkang PAN Zhimin ZHENG Lajos HANZO Xuemin(Sherman)SHEN Yingjie Jay GUO Zhiguo DING Harald HAAS Wen TONG Peiying ZHU Ganghua YANG Jun WANG Erik GLARSSON Hien Quoc NGO Wei HONG Haiming WANG Debin HOU Jixin CHEN Zhe CHEN Zhangcheng HAO Geoffrey Ye LI Rahim TAFAZOLLI Yue GAO HVincent POOR Gerhard P.FETTWEIS Ying-Chang LIANG | 2021 | Science China(Information Sciences)2021，64，1： | 122 |
| 6 | China Stroke Statistics 2019:A Report From the National Center for Healthcare Quality Management in Neurological Diseases,China National Clinical Research Center for Neurological Diseases,the Chinese Stroke Association,National Center for Chronic and Non-communicable Disease Control and Prevention,Chinese Center for Disease Control and Prevention and Institute for Global Neuroscience and Stroke Collaborations显示文摘China faces the greatest challenge from stroke in the world.The death rate for cerebrovascular diseases in China was 149.49 per 100000,accounting for 1.57 million deaths in 2018.It ranked third among the leading causes of death behind malignant tumours and heart disease.The age-standardised prevalence and incidence of stroke in 2013 were 1114.8 per 100000 population and 246.8 per 100000 person-years,respectively.According to the Global Burden of Disease Study 2017,the years of life lost(YLLs)per 100000 population for stroke increased by 14.6%;YLLs due to stroke rose from third highest among all causes in 1990 to the highest in 2017.The absolute numbers and rates per 100000 population for all-age disability-adjusted life years(DALYs)for stroke increased substantially between 1990 and 2017,and stroke was the leading cause of all-age DALYs in 2017.The main contributors to cerebrovascular diseases include behavioural risk factors(smoking and alcohol use)and pre-existing conditions(hypertension,diabetes mellitus,dyslipidaemia and atrial fibrillation(AF)).The most prevalent risk factors among stroke survivors were hypertension(63.0%-84.2%)and smoking(31.7%-47.6%).The least prevalent was AF(2.7%-7.4%).The prevalences for major risk factors for stroke are high and most have increased over time.Based on the latest national epidemiological data,26.6%of adults aged≥15 years(307.6 million adults)smoked tobacco products.For those aged≥18 years,age-adjusted prevalence of hypertension was 25.2%;adjusted prevalence of hypercholesterolaemia was 5.8%;and the standardised prevalence of diabetes was 10.9%.For those aged≥40 years,the standardised prevalence of AF was 2.31%.Data from the Hospital Quality Monitoring System showed that 3010204 inpatients with stroke were admitted to 1853 tertiary care hospitals during 2018.Of those,2466785(81.9%)were ischaemic strokes(ISs);447609(14.9%)were intracerebral haemorrhages(ICHs);and 95810(3.2%)were subarachnoid haemorrhages(SAHs).The average age of patients admitted was 66 years old,and nearly 60%were male.A total of 1555(0.1%),2774(0.6%)and 1347(1.4%)paediatric strokes(age<18 years)were identified among IS,ICH and SAH,respectively.Over one-third(1063892(35.3%))of the patients were covered by urban resident basic medical insurance,followed by urban employee basic medical insurance(699513(23.2%))and new rural cooperative medical schema(489361(16.3%)).The leading risk factor was hypertension(67.4%for IS,77.2%for ICH and 49.1%for SAH),and the leading comorbidity was pneumonia or pulmonary infection(10.1%for IS,31.4%for ICH and 25.2%for SAH).In-hospital death/discharge against medical advice rate was 8.3%for stroke inpatients,ranging from 5.8%for IS to 19.5%for ICH.The median and IQR of length of stay was 10.0(7.0-14.0)days,ranging from 10.0(7.0-13.0)in IS to 14.0(8.0-22.0)in SAH.Data from the Chinese Stroke Center Alliance demonstrated that the composite scores of guideline-recommended key performance indicators for patients with IS,ICH and SAH were 0.77±0.21,0.72±0.28 and 0.59±0.32,respectively. | Yong-Jun Wang Zi-Xiao Li Hong-Qiu Gu Yi Zhai Yong Jiang Xing-Quan Zhao Yi-Long Wang Xin Yang Chun-Juan Wang Xia Meng Hao Li Li-Ping Liu Jing Jing Jing Wu An-Ding Xu Qiang Dong David Wang Ji-Zong Zhao On behalf of China Stroke Statistics 2019 Writing Committee | 2020 | Stroke & Vascular Neurology2020，5，3： | 181 |
| 7 | The Chinese Society of Clinical Oncology(CSCO):clinical guidelines for the diagnosis and treatment of gastric cancer显示文摘China is one of the countries with the highest incidence of gastric cancer.There are differences in epidemiological characteristics,clinicopathological features,tumor biological characteristics,treatment patterns,and drug selection between gastric cancer patients from the Eastern and Western countries.Non-Chinese guidelines cannot specifically reflect the diagnosis and treatment characteristics for the Chinese gastric cancer patients.The Chinese Society of Clinical Oncology(CSCO)arranged for a panel of senior experts specializing in all sub-specialties of gastric cancer to compile,discuss,and revise the guidelines on the diagnosis and treatment of gastric cancer based on the findings of evidence-based medicine in China and abroad.By referring to the opinions of industry experts,taking into account of regional differences,giving full consideration to the accessibility of diagnosis and treatment resources,these experts have conducted experts’consensus judgement on relevant evidence and made various grades of recommendations for the clinical diagnosis and treatment of gastric cancer to reflect the value of cancer treatment and meeting health economic indexes.This guideline uses tables and is complemented by explanatory and descriptive notes covering the diagnosis,comprehensive treatment,and follow-up visits for gastric cancer. | Feng-Hua Wang Lin Shen Jin Li Zhi-Wei Zhou Han Liang Xiao-Tian Zhang Lei Tang Yan Xin Jing Jin Yu-Jing Zhang Xiang-Lin Yuan Tian-Shu Liu Guo-Xin Li Qi Wu Hui-Mian Xu Jia-Fu Ji Yuan-Fang Li Xin Wang Shan Yu Hao Liu Wen-Long Guan Rui-Hua Xu | 2019 | Cancer Communications2019，39，1： | 127 |
| 8 | The Chinese Society of Clinical Oncology(CSCO):Clinical guidelines for the diagnosis and treatment of gastric cancer,2021显示文摘There exist differences in the epidemiological characteristics,clinicopathological features,tumor biological characteristics,treatment patterns,and drug selections between gastric cancer patients from the Eastern and Western countries.The Chinese Society of Clinical Oncology(CSCO)has organized a panel of senior experts specializing in all sub-specialties of gastric cancer to compile a clinical guideline for the diagnosis and treatment of gastric cancer since 2016 and renews it annually.Taking into account regional differences,giving full consideration to the accessibility of diagnosis and treatment resources,these experts have conducted expert consensus judgment on relevant evidence and made various grades of recommendations for the clinical diagnosis and treatment of gastric cancer to reflect the value of cancer treatment and meeting health economic indexes in China.The 2021 CSCO Clinical Practice Guidelines for Gastric Cancer covers the diagnosis,treatment,follow-up,and screening of gastric cancer.Based on the 2020 version of the CSCO Chinese Gastric Cancer guidelines,this updated guideline integrates the results ofmajor clinical studies from China and overseas for the past year,focused on the inclusion of research data from the Chinese population for more personalized and clinically relevant recommendations.For the comprehensive treatment of non-metastatic gastric cancer,attentions were paid to neoadjuvant treatment.The value of perioperative chemotherapy is gradually becoming clearer and its recommendation level has been updated.For the comprehensive treatment of metastatic gastric cancer,recommendations for immunotherapy were included,and immune checkpoint inhibitors fromthird-line to the first-line of treatment for different patient groups with detailed notes are provided. | Feng-Hua Wang Xiao-Tian Zhang Yuan-Fang Li Lei Tang Xiu-Juan Qu Jie-Er Ying Jun Zhang Ling-Yu Sun Rong-Bo Lin Hong Qiu Chang Wang Miao-Zhen Qiu Mu-Yan Cai QiWu Hao Liu Wen-Long Guan Ai-Ping Zhou Yu-Jing Zhang Tian-Shu Liu Feng Bi Xiang-Lin Yuan Sheng-Xiang Rao Yan Xin Wei-Qi Sheng Hui-Mian Xu Guo-Xin Li Jia-Fu Ji Zhi-Wei Zhou Han Liang Yan-Qiao Zhang Jing Jin Lin Shen Jin Li Rui-Hua Xu | 2021 | Cancer Communications2021，41，8： | 97 |
| 9 | Clinical characteristics, diagnosis and management of respiratory distress syndrome in full-term neonates显示文摘然而,背景呼吸悲痛症候群(RDS ) 是新生的呼吸失败和新生的死亡的最普通的原因之一它的临床的特征与早熟的 RDS,和这些特征很不同很好没迄今为止被记录。这研究是在完整术语的出生不满一月的婴儿调查致病,临床的特征和 RDS 的管理策略,与开发为改进在有 RDS.Methods 的完整术语的出生不满一月的婴儿的结果的一个工作协议的目的有 RDS 的 125 个完整术语的婴儿的一个总数在这研究被注册。他们的临床并且实验室数据为分析 125 个案例包括了的完整术语的新生的 RDS.Results (1 ) 的特征被收集 94 男性和 31 个女婴儿,阴道交货在 45 种情况中发生在 80 种情况和剖腹产中。(2 ) RDS 的发作时间是(3.11 牧潯敶吗? | LIU Jing SHI Yun DONG Jian-ying ZHENG Tian LI Jing-ya LU Li-li LIU Jing-jing LIANG Jing ZHANG Hao FENG Zhi-chun | 2010 | Chinese Medical Journal2010，，19： | 79 |
| 10 | 5-methylcytosine promotes mRNA export--NSUN2 as the methyltransferase and ALYREF as an m5C reader显示文摘 | Yang, Xin Yang, Ying Sun, Bao-Fa Chen, Yu-Sheng Xu, Jia-Wei Lai, Wei-Yi Li, Ang Wang, Xing Bhattarai, Devi Prasad Xiao, Wen Sun, Hui-Ying Zhu, Qin Ma, Hai-Li Adhikari, Samir Sun, Min Hao, Ya-Juan Zhang, Bing Huang, Chun-Min Huang, Niu Jiang, Gui-Bin Zhao, Yong-Liang Wang, Hai-Lin Sun, Ying-Pu Yang, Yun-Gui | 2017 | Cell Research2017，27，5： | 62 |
| 11 | High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa显示文摘It has been reported that ACE2 is the main host cell receptor of 2019-nCoV and plays a crucial role in the entry of virus into the cell to cause the final infection. To investigate the potential route of 2019-n Cov infection on the mucosa of oral cavity, bulk RNA-seq profiles from two public databases including The Cancer Genome Atlas(TCGA) and Functional Annotation of The Mammalian Genome Cap Analysis of Gene Expression(FANTOM5 CAGE) dataset were collected. RNA-seq profiling data of 13 organ types with para-carcinoma normal tissues from TCGA and 14 organ types with normal tissues from FANTOM5 CAGE were analyzed in order to explore and validate the expression of ACE2 on the mucosa of oral cavity. Further, single-cell transcriptomes from an independent data generated in-house were used to identify and confirm the ACE2-expressing cell composition and proportion in oral cavity. The results demonstrated that the ACE2 expressed on the mucosa of oral cavity. Interestingly, this receptor was highly enriched in epithelial cells of tongue. Preliminarily, those findings have explained the basic mechanism that the oral cavity is a potentially high risk for 2019-nCoV infectious susceptibility and provided a piece of evidence for the future prevention strategy in dental clinical practice as well as daily life. | Hao Xu Liang Zhong Jiaxin Deng Jiakuan Peng Hongxia Dan Xin Zeng Taiwen Li Qianming Chen | 2020 | International Journal of Oral Science2020，12，1： | 69 |
| 12 | Artificial intelligence in healthcare:past,present and future显示文摘Artificial intelligence(AI)aims to mimic human cognitive functions.It is bringing a paradigm shift to healthcare,powered by increasing availability of healthcare data and rapid progress of analytics techniques.We survey the current status of AI applications in healthcare and discuss its future.AI can be applied to various types of healthcare data(structured and unstructured).Popular AI techniques include machine learning methods for structured data,such as the classical support vector machine and neural network,and the modern deep learning,as well as natural language processing for unstructured data.Major disease areas that use AI tools include cancer,neurology and cardiology.We then review in more details the AI applications in stroke,in the three major areas of early detection and diagnosis,treatment,as well as outcome prediction and prognosis evaluation.We conclude with discussion about pioneer AI systems,such as IBM Watson,and hurdles for real-life deployment of AI. | Fei Jiang Yong Jiang Hui Zhi Yi Dong Hao Li Sufeng Ma Yilong Wang Qiang Dong Haipeng Shen Yongjun Wang | 2017 | Stroke & Vascular Neurology2017，2，4： | 76 |
| 13 | Treatment of patients with severe sepsis using Ulinastatin and Thymosin al: a prospective, randomized, controlled pilot study显示文摘 | CHEN Hao HE Ming-yan LI Yu-min | 2009 | Chinese Medical Journal2009，，8： | 51 |
| 14 | Characterization and assessment of volatile organic compounds (VOCs) emissions from typical industries显示文摘VOCs play an increasingly important role in affecting air quality and threatening human health in China in recent years,where industry activities show a significant contribution to VOCs emission.In this article we report our long term study of industrial VOCs emissions of six major industries (vehicle manufacturing,printing,equipment coating,electronic manufacturing,furniture manufacturing and bio-pharming) on the aspects of emission characteristics,environmental impact and health risk assessment,and control challenge analysis with the purpose to obtain in-depth understanding of industry VOCs emissions and offer some original basements for national control and management of industry VOCs emissions.This study shows that all these industries give middle or low emission with total VOCs concentration less than 1000 mg/m3 at each exhaust pipe.Benzenes,esters,alcohols,ketones,alkanes,chloroalkanes and alkenes were detected as the major emission components and the most frequently monitored VOCs were benzenes,which varied obviously with different processes and industries.The environmental impact assessments indicate that vehicle manufacturing and benzenes should be prior controlled with the purpose to reduce air pollution.While,health risk assessments suggest that furniture manufacturing and chloroalkanes should be firstly controlled.Control analysis indicates that developing technologies with low cost and high efficiency and establishing and completing specific industry emission standards/regulations are the two key issues in VOCs emission management at present stage. | WANG HaiLin NIE Lie LI Jing WANG YuFei WANG Gang WANG JunHui HAO ZhengPing | 2013 | Science China(Technological Sciences)2013，56，3： | 60 |
| 15 | Efficacy of cattle encephalon glycoside and ignotin in patients with acute cerebral infarction: a randomized, double-blind, parallel-group, placebo-controlled study显示文摘Cattle encephalon glycoside and ignotin(CEGI)injection is a compound preparation formed by a combination of muscle extract from hea lthy rabbits and brain gangliosides from cattle,and it is generally used as a neuroprotectant in the treatment of central and peripheral nerve injuries.However,there is still a need for high-level clinical evidence from large samples to support the use of CEGI.We therefore carried out a prospective,multicenter,randomized,double-blind,parallel-group,placebo-controlled study in which we recruited 319 patients with acute cerebral infarction from 16 centers in China from October 2013 to May 2016.The patients were randomized at a 3:1 ratio into CEGI(n=239;155 male,84 female;61.2±9.2 years old)and placebo(n=80;46 male,34 female;63.2±8.28 years old)groups.All patients were given standard care once daily for 14 days,including a 200 mg aspirin enteric-coated tablet and 20 mg atorvastatin calcium,both taken orally,and intravenous infusion of 250–500 mL 0.9%sodium chloride containing 40 mg sodium tanshinone IIA sulfonate.Based on conventional treatment,patients in the CEGI and placebo groups were given 12 mL CEGI or 12 mL sterile water,respectively,in an intravenous drip of 250 mL 0.9%sodium chloride(2 mL/min)once daily for 14 days.According to baseline National Institutes of Health Stroke Scale scores,patients in the two groups were divided into mild and moderate subgroups.Based on the modified Rankin Scale results,the rate of patients with good outcomes in the CEGI group was higher than that in the placebo group,and the rate of disability in the CEGI group was lower than that in the placebo group on day 90 after treatment.In the CEGI group,neurological deficits were decreased on days 14 and 90 after treatment,as measured by the National Institutes of Health Stroke Scale and the Barthel Index.Subgroup analysis revealed that CEGI led to more significant improvements in moderate stroke patients.No drug-related adverse events occurred in the CEGI or placebo groups.In conclusion,CEGI may be a safe and effective treatment for acute cerebral infarction patients,especially for moderate stroke patients.This study was approved by the Ethical Committee of Peking University Third Hospital,China(approval No.2013-068-2)on May 20,2013,and registered in the Chinese Clinical Trial Registry(registration No.ChiCTR1800017937). | Hui Zhang Chuan-Ling Li Feng Wan Su-Juan Wang Xiu-E Wei Yan-Lei Hao Hui-Lin Leng Jia-Min Li Zhong-Rui Yan Bao-Jun Wang Ren-Shi Xu Ting-Min Yu Li-Chun Zhou Dong-Sheng Fan | 2020 | Neural Regeneration Research2020，15，7： | 54 |
| 16 | Contrasting trends of PM2.5 and surface-ozone concentrations in China from 2013 to 2017显示文摘Although much attention has been paid to investigating and controlling air pollution in China,the trends of air-pollutant concentrations on a national scale have remained unclear.Here,we quantitatively investigated the variation of air pollutants in China using long-term comprehensive data sets from 2013 to 2017,during which Chinese government made major efforts to reduce anthropogenic emission in polluted regions.Our results show a significant decreasing trend in the PM2.5 concentration in heavily polluted regions of eastern China,with an annual decrease of〜7%compared with measurements in 2013.The measured decreased concentrations of SO2>NO2 and CO(a proxy for anthropogenic volatile organic compounds)could explain a large fraction of the decreased PM2.5 concentrations in different regions.As a consequence;the heavily polluted days decreased significantly in corresponding regions.Concentrations of organic aerosol;nitrate;sulfate,ammonium and chloride measured in urban Beijing revealed a remarkable reduction from 2013 to 2017;connecting the decreases in aerosol precursors with corresponding chemical components closely.However;surface-ozone concentrations showed increasing trends in most urban stations from 2013 to 2017;which indicates stronger photochemical pollution.The boundary-layer height in capital c让ies of eastern China showed no significant trends over the Beijing-Tianjin-Hebei,Yangtze River Delta and Pearl River Delta regions from 2013 to 2017;which confirmed the reduction in anthropogenic emissions.Our results demonstrated that the Chinese government was successful in the reduction of particulate matter in urban areas from 2013 to 2017,although the ozone concentration has increased significantly;suggesting a more complex mechanism of improving Chinese air quality in the future. | Yonghong Wang Wenkang Gao Shuai Wang Tao Song Zhengyu Gong Dongsheng Ji Lili Wang Zirui Liu Guiqian Tang Yanfeng Huo Shili Tian Jiayun Li Mingge Li Yuan Yang Biwu Chu Tuukka Petaja Veli-Matti Kerminen Hong He Jiming Hao Markku Kulmala Yuesi Wang Yuanhang Zhang | 2020 | National Science Review2020，7，8： | 51 |
| 17 | Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies显示文摘Locoregional spread of abdominopelvic malignant tumors frequently results in peritoneal carcinomatosis(PC). The prognosis of PC patients treated by conventional systemic chemotherapy is poor, with a median survival of < 6 mo. However, over the past three decades, an integrated treatment strategy of cytoreductive surgery(CRS) + hyperthermic intraperitoneal chemotherapy(HIPEC) has been developed by the pioneering oncologists, with proved efficacy and safety in selected patients. Supported by several lines of clinical evidence from phases Ⅰ, Ⅱ and Ⅲ clinical trials, CRS + HIPEC has been regarded as the standard treatment for selected patients with PC in many established cancer centers worldwide. In China, an expert consensus on CRS + HIPEC has been reached by the leading surgical and medical oncologists, under the framework of the China Anti-Cancer Association. This expert consensus has summarized the progress in PC clinical studies and systematically evaluated the CRS + HIPEC procedures in China as well as across the world, so as to lay the foundation for formulating PC treatment guidelines specific to the national conditions of China. | Yan Li Yun-Feng Zhou Han Liang Hua-Qing Wang Ji-Hui Hao Zheng-Gang Zhu De-Seng Wan Lun-Xiu Qin Shu-Zhong Cui Jia-Fu Ji Hui-Mian Xu Shao-Zhong Wei Hong-Bin Xu Tao Suo Shu-Jun Yang Cong-Hua Xie Xiao-Jun Yang Guo-Liang Yang | 2016 | World Journal of Gastroenterology2016，22，30： | 58 |
| 18 | Surgical outcomes of mini-open Wiltse approach and conventional open approach in patients with single-segment thoracolumbar fractures without neurologic injury显示文摘This study aimed to introduce a novel mini-open pedicle screw fixation technique via Wiltse approach,and compared it with the traditional posterior open method.A total of 72 cases of single-segment thoracolumbar fractures without neurologic injury underwent pedicle screw fixation via two different approaches.Among them,37 patients were treated using posterior open surgery,and 35 patients received mini-open operation via Wiltse approach.Crew placement accuracy rate,operative time,blood loss,postoperative drainage,postoperative hospitalization time,radiation exposure time,postoperative improvement in R value,Cobb's angle and visual analog scale(VAS)scores of the two methods were compared.There were no significant differences in the accuracy rate of pedicle screw placement,radiation exposure and postoperative R value and Cobb's angle improvement between the two groups.However,the mini-open method had obvious advantages over the conventional open method in operative time,blood loss,postoperative drainage,postoperative hospitalization time,and postoperative improvement in VAS.The mini-open pedicle screw technique could be applied in treatment of single-segment thoracolumbar fracture without neurologic injury and had advantages of less tissue trauma,short operative and rehabilitative time on the premise of guaranteed accuracy rate and no increased radiation exposure. | Haijun Li Lei Yang Hao Xie Lipeng Yu Haifeng Wei Xiaojian Cao | 2015 | The Journal of Biomedical Research2015，29，1： | 43 |
| 19 | Plasma exchange-centered artificial liver support system in hepatitis B virus-related acute-onchronic liver failure:a nationwide prospective multicenter study in China显示文摘BACKGROUND:Plasma exchange(PE)-centered artificial liver support system reduced the high mortality rate of hepatitis B virus(HBV)-related acute-on-chronic liver failure(ACLF).But the data were diverse in different medical centers.The present prospective nationwide study was to evaluate the effects of PE on patients with HBV-ACLF at different stages.METHODS:From December 2009 to December 2011,we evaluated 250 patients at different stages of HBV-ACLF from 10 major medical centers in China.All the laboratory parameters were collected at admission,before and after PE.RESULTS:Among the 250 patients who underwent 661 rounds of PE,one-month survival rate was 61.6%; 141(56.4%) showed improvement after PE.Variables such as age(P=0.000),levels of total bilirubin(TB,P=0.000),direct bilirubin(P=0.000),total triglycerides(P=0.000),low-density lipoprotein(P=0.022),Na+(P=0.014),Cl–(P=0.038),creatinine(Cr,P=0.007),fibrinogen(P=0.000),prothrombin time(PT,P=0.000),white blood cell(P=0.000),platelet(P=0.003) and MELD(P=0.000) were significantly related to prognosis.Multivariate logistic regression analysis showed that age,disease stage,TB,Cr and PT levels were independent risk factors of mortality among HBV-ACLF patients.CONCLUSIONS:PE can improve the clinical outcome of patients with HBV-ACLF.Levels of TB,Cr and PT,age and disease stage help to predict prognosis. | Jia-Jia Chen Jian-Rong Huang Qian Yang Xiao-Wei Xu Xiao-Li Liu Shao-Rui Hao Hui-Fen Wang Tao Han Jing Zhang Jian-He Gan Zhi-Liang Gao Yu-Ming Wang Shu-Mei Lin Qing Xie Chen Pan Lan-Juan Li | 2016 | Hepatobiliary & Pancreatic Diseases International2016，15，3： | 48 |
| 20 | Rapid improvement of grain weight via highly efficient CRISPR/Cas9-mediated multiplex genome editing in rice显示文摘Most of the important agronomic traits in crop plants,such as yield,quality and stress response,are quantitative and jointly controlled by many genomic loci or major genes.Improving these complex traits depends on the combination of beneficial alleles at the quantitative trait loci(QTLs).However,the conventional cross breeding method is extremely time-consuming and laborious for pyramiding multiple QTLs.In certain cases,this approach | Rongfang Xu Yachun Yang Ruiying Qin Hao Li Chunhong Qiu Li Li Pengcheng Wei Jianbo Yang | 2016 | Journal of Genetics and Genomics2016，43，8： | 47 |
您所在的机构暂未开通此部分的功能，请联系管理员